Jaguar Health Inc (JAGX)

$1.98 +0.21 (11.86%)
Market Cap 3.85M
Revenue (ttm) 11.69M
Net Income (ttm) -38.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -329.26%
Debt to Equity Ratio 1.56
Volume 288,300
Avg Vol 115,292
Day's Range N/A - N/A
Shares Out 2.18M
Stochastic %K 95%
Beta 0.58
Analysts Sell
Price Target $16.00

Company Profile

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infe...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 371 8300
Address:
200 Pine Street, Suite 400, San Francisco, United States
leroyburns
leroyburns Sep. 9 at 4:30 PM
$JAGX Unitronix pre breakout structure forming higher lows pinching under resistance classic coil setup often resolves up with authority 📣
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 9 at 1:05 PM
$NUWE $SINT $BDRX $JAGX !
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Sep. 9 at 12:33 PM
$JAGX make me rich!
0 · Reply
ExecutiveEdge
ExecutiveEdge Sep. 9 at 1:13 AM
I called OCTO to a tee check this photo 🔽⏬🔽 Now I am calling 🚨MSS🚨 this can easily 5x, they are profitable with no company selling and strong insider ownership …. $JAGX $OPEN $HIMS $OSCR
0 · Reply
NextRunnerTV
NextRunnerTV Sep. 9 at 12:09 AM
🚨🚨NEW VIDEO OUT🚨🚨 SO MANY HAVE WENT MASSIVE, THIS COULD BE NEXT ⬇️⬇️⬇️⬇️ https://www.tiktok.com/t/ZT63NYuQF/ $OCTO $NBIS $JAGX
1 · Reply
axlgregory
axlgregory Sep. 8 at 3:05 PM
$JAGX NXXT volume building quietly then bursts through resistance watch vwap hold and bids stack under pushes could snowball fast 📈
0 · Reply
Kikic
Kikic Sep. 5 at 8:28 PM
$JAGX eez 90% Captain 🤙
0 · Reply
investimakerrr
investimakerrr Sep. 5 at 4:40 PM
$JAGX got my 1k sh parked!
1 · Reply
JaguarHealthInc
JaguarHealthInc Sep. 5 at 1:40 PM
Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts https://bit.ly/4mOBY9t $JAGX
0 · Reply
The_Gambl3r
The_Gambl3r Sep. 5 at 1:37 PM
$JAGX
0 · Reply
Latest News on JAGX
Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

Sep 5, 2025, 9:00 AM EDT - 4 days ago

Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs

Aug 21, 2025, 9:00 AM EDT - 19 days ago

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders

Aug 19, 2025, 4:15 PM EDT - 20 days ago

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders

Jaguar Health, Inc. (JAGX) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 3:43 PM EDT - 20 days ago

Jaguar Health, Inc. (JAGX) Q2 2025 Earnings Call Transcript

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

Aug 19, 2025, 9:00 AM EDT - 21 days ago

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

Aug 14, 2025, 8:00 AM EDT - 26 days ago

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

Aug 12, 2025, 9:00 AM EDT - 4 weeks ago

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Jul 10, 2025, 8:30 AM EDT - 2 months ago

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca

Jul 8, 2025, 9:00 AM EDT - 2 months ago

Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

Jun 30, 2025, 9:00 AM EDT - 2 months ago

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Jun 26, 2025, 9:00 AM EDT - 2 months ago

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Jun 25, 2025, 9:00 AM EDT - 2 months ago

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

Jun 24, 2025, 4:15 PM EDT - 2 months ago

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Jun 23, 2025, 9:00 AM EDT - 2 months ago

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Jun 17, 2025, 9:00 AM EDT - 3 months ago

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Jun 11, 2025, 10:00 AM EDT - 3 months ago

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series

Jun 9, 2025, 4:15 PM EDT - 3 months ago

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

Jun 9, 2025, 9:00 AM EDT - 3 months ago

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series

Jun 6, 2025, 9:00 AM EDT - 3 months ago

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 21, 2025, 8:00 AM EDT - 3 months ago

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)

May 20, 2025, 9:15 AM EDT - 4 months ago

First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)

Jaguar Health, Inc. (JAGX) Q1 2025 Earnings Call Transcript

May 15, 2025, 8:43 PM EDT - 4 months ago

Jaguar Health, Inc. (JAGX) Q1 2025 Earnings Call Transcript

Jaguar Health Reports First Quarter 2025 Financials

May 15, 2025, 2:30 PM EDT - 4 months ago

Jaguar Health Reports First Quarter 2025 Financials

Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates

May 14, 2025, 9:00 AM EDT - 4 months ago

Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates

Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

May 8, 2025, 9:30 AM EDT - 4 months ago

Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts

May 7, 2025, 9:15 AM EDT - 4 months ago

Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts

Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients

Apr 30, 2025, 8:15 AM EDT - 4 months ago

Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients

REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Apr 29, 2025, 4:15 PM EDT - 4 months ago

REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast

Apr 28, 2025, 8:15 AM EDT - 4 months ago

Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast

Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress

Apr 17, 2025, 9:00 AM EDT - 5 months ago

Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

Apr 15, 2025, 9:30 AM EDT - 5 months ago

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

Apr 8, 2025, 8:30 AM EDT - 5 months ago

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 4, 2025, 4:15 PM EDT - 5 months ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

Apr 1, 2025, 4:15 PM EDT - 5 months ago

Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 9:57 AM EDT - 5 months ago

Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call Transcript

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

Mar 31, 2025, 8:00 AM EDT - 5 months ago

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

Mar 28, 2025, 9:00 AM EDT - 5 months ago

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study

Mar 27, 2025, 8:30 AM EDT - 5 months ago

Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study

Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts

Mar 26, 2025, 11:00 AM EDT - 5 months ago

Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts

Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules

Mar 26, 2025, 9:25 AM EDT - 5 months ago

Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules

Jaguar Health, Inc. Announces Reverse Stock Split

Mar 18, 2025, 8:30 AM EDT - 6 months ago

Jaguar Health, Inc. Announces Reverse Stock Split

Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders

Mar 13, 2025, 4:15 PM EDT - 6 months ago

Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders

Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value

Feb 27, 2025, 8:30 AM EST - 6 months ago

Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value

Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Feb 19, 2025, 9:00 AM EST - 7 months ago

Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300

Feb 18, 2025, 9:00 AM EST - 7 months ago

Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300

Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Feb 13, 2025, 9:05 AM EST - 7 months ago

Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference

Feb 6, 2025, 10:00 AM EST - 7 months ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025

Feb 3, 2025, 9:30 AM EST - 7 months ago

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025

Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO

Jan 29, 2025, 8:30 AM EST - 7 months ago

Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO

Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025

Jan 22, 2025, 9:00 AM EST - 8 months ago

Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025

leroyburns
leroyburns Sep. 9 at 4:30 PM
$JAGX Unitronix pre breakout structure forming higher lows pinching under resistance classic coil setup often resolves up with authority 📣
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 9 at 1:05 PM
$NUWE $SINT $BDRX $JAGX !
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Sep. 9 at 12:33 PM
$JAGX make me rich!
0 · Reply
ExecutiveEdge
ExecutiveEdge Sep. 9 at 1:13 AM
I called OCTO to a tee check this photo 🔽⏬🔽 Now I am calling 🚨MSS🚨 this can easily 5x, they are profitable with no company selling and strong insider ownership …. $JAGX $OPEN $HIMS $OSCR
0 · Reply
NextRunnerTV
NextRunnerTV Sep. 9 at 12:09 AM
🚨🚨NEW VIDEO OUT🚨🚨 SO MANY HAVE WENT MASSIVE, THIS COULD BE NEXT ⬇️⬇️⬇️⬇️ https://www.tiktok.com/t/ZT63NYuQF/ $OCTO $NBIS $JAGX
1 · Reply
axlgregory
axlgregory Sep. 8 at 3:05 PM
$JAGX NXXT volume building quietly then bursts through resistance watch vwap hold and bids stack under pushes could snowball fast 📈
0 · Reply
Kikic
Kikic Sep. 5 at 8:28 PM
$JAGX eez 90% Captain 🤙
0 · Reply
investimakerrr
investimakerrr Sep. 5 at 4:40 PM
$JAGX got my 1k sh parked!
1 · Reply
JaguarHealthInc
JaguarHealthInc Sep. 5 at 1:40 PM
Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts https://bit.ly/4mOBY9t $JAGX
0 · Reply
The_Gambl3r
The_Gambl3r Sep. 5 at 1:37 PM
$JAGX
0 · Reply
schrisrice
schrisrice Sep. 4 at 3:45 PM
$JAGX Only down 88% over the past six months. Great investment opportunity if you have money to burn.
0 · Reply
TimeForChangeNow
TimeForChangeNow Sep. 4 at 2:59 PM
$JAGX lol selling at 2.59 for a small loss was a good move lower lows coming. Be careful here no success, like BIOC years of lies and no bankrupt. GLTAL.
0 · Reply
frittenpit2019
frittenpit2019 Sep. 4 at 2:39 PM
$JAGX Which idiot is investing in this trash???
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 3 at 11:14 AM
$SINT initiated countdown timer mechanism will mobilize for markets $RFL $JAGX $BDRX $NUWE pivoting
0 · Reply
richiehasfuntrading
richiehasfuntrading Sep. 2 at 11:57 AM
$JAGX Take it from me, not even good enough to be a rookie. Buy this stock! You know how the people that don't know crap seem to pick winning stocks. That's me. Thank me later.
2 · Reply
MarketManStockWizzard
MarketManStockWizzard Aug. 29 at 9:55 PM
$JAGX Lincoln Alternative Strategies LLC https://disclosurequest.com/form/lincoln-alternative-strategies-llc/0002043812-25-000001 This guy is a shyster. Hes under an atm himself... using funds he sells to manipulate other stocks.
0 · Reply
richiehasfuntrading
richiehasfuntrading Aug. 29 at 3:12 PM
$JAGX Just bought at ask! I not sceeerd. This is one of those stocks I see all negative comments and the price that has gone down considerably. That's when you buy! Unless you are a day trader or can't wait a few months.
3 · Reply
Oruveek70
Oruveek70 Aug. 29 at 4:53 AM
$JAGX I stated that I wasn't going to post here again however... you know a catalyst can, in theory, send the share price skyrocketing but the reality is that there's little relief from the dilution and reverse splits.
0 · Reply
Tabi04
Tabi04 Aug. 29 at 1:56 AM
$JAGX heading lower
0 · Reply
richiehasfuntrading
richiehasfuntrading Aug. 28 at 10:50 PM
$JAGX Just bought at a nice price.
1 · Reply
htl23
htl23 Aug. 28 at 9:02 PM
$JAGX Any thoughts ?
4 · Reply
schrisrice
schrisrice Aug. 28 at 3:02 PM
$JAGX Reverse split incoming... I'd guess the chatter will start as we near a dollar.
0 · Reply